Anjieming Medical Secures Tens of Millions in Pre-A Funding to Advance Glaucoma Diagnostic Innovations
AGMED
Medical Device Provider
Recently, AGMED, an angel round project of Beihang Investment, announced the completion of a Pre-A round financing worth tens of millions of RMB.
AGMed Technology Limited, led by a postdoctoral team from the Hong Kong University of Science and Technology and co-founded with the National Innovation Center for High-Performance Medical Devices, is a joint venture that has developed several globally pioneering products. By integrating mechanical engineering with healthcare, the company has established a new standard for early glaucoma diagnosis. Beihang Investment, focusing on the intersection of medical and engineering fields, is one of AGMed's earliest and most significant supporters, continuously backing and accompanying the company’s growth.
(AGMed Founder & CEO Zhen Qin has been invited by Beihang Investment to participate in events multiple times. Left: Participating in the industry matchmaking conference and project presentation at China Eye Valley; Right: Roadshow presentation at the Beihang Investment Medical-Engineering Cross Innovation Roadshow.)
On November 13, AGMed Technology Limited (hereinafter referred to as "AGMED") completed a Pre-A round of financing worth tens of millions of RMB. This round of financing was led by Hengqin Venture Capital, with participation from Shanghai Rongwang and other strategic industry capital. Existing shareholder, Shenzhen Qianhai Yuanming Investment Management Co., Ltd., continued to support the company.
This round of financing has provided important financial support for the development of AGMed Technology Limited. The funds will mainly be used to accelerate the clinical trials and registration applications of innovative medical devices — the continuous intraocular pressure monitoring system, marketization of the corneal analysis system, as well as the expansion and upgrading of the team.
AGMed Technology Limited was established on October 13, 2021, as an innovative medical technology company specializing in the ophthalmology field. Starting with early-stage glaucoma diagnostic equipment, the company is developing an integrated solution for full-cycle diagnosis and treatment, committed to providing patients with safe, efficient, and precise medical devices while contributing to the visual health of a broader population in China. The company collaborates with multiple research institutions and hospitals, including the Hong Kong University of Science and Technology, Zhongshan Ophthalmic Center of Sun Yat-sen University, and Shenzhen People's Hospital, to jointly advance world-leading technology research and development, achieving breakthroughs in high-end ophthalmic diagnostic and treatment equipment and systems produced in China.
After three years of relentless efforts, AGMed has made significant achievements in its product pipeline and is proceeding as scheduled. We would like to thank the investment institutions that have consistently supported AGMed. AGMed will continue to focus on technological breakthroughs and accelerate the industrialization process, bringing more convenient and accurate diagnostic and therapeutic devices to patients.
The successful closing of this round of financing marks an important progress in the continuous development of AGMed Technology Limited. It also provides strong financial support to accelerate the launch of key products, the corneal analysis system and the intraocular pressure monitoring system, fully demonstrating the investment institutions' recognition of AGMed's innovative technology in the field of glaucoma diagnosis and treatment as well as their confidence in the company’s future development.
In addition to AGMed, Beihang Investment has also invested in a large number of leading companies in the field of medical-engineering integration. In the future, Beihang Investment will continue to...Cultivate early-stage hard tech startup projects and accompany scientific entrepreneurs in their growth.
Part of Beihang Investment's Medical-Engineering Cross-Disciplinary Investment Cases
Core Medical
Core Medical focuses on the research, development, and production of high-end innovative medical device products such as mechanical circulatory assist devices (commonly known as "artificial hearts"). It has achieved a comprehensive layout in the field of implantable and interventional artificial hearts, aiming to provide a full range of solutions for heart failure patients worldwide. The key performance indicators of Core Medical's self-developed ultra-small full magnetic levitation artificial heart, Corheart® 6, have reached the same level as international counterparts, significantly enhancing the competitiveness of domestically produced artificial hearts in the global market.
Unmag Technology
Weici Technology is one of the very few quasi-unicorn companies in the world that owns the underlying technology for quantum precision magnetic field measurement, including optically pumped magnetometers, magnetocardiography (MCG) systems, and magnetoencephalography (MEG) systems across the entire industrial chain. With the core technology platform of quantum precision magnetic field measurement—optically pumped magnetometers—the company has successfully developed high-end medical imaging equipment such as MCG and MEG systems with fully independent intellectual property rights. It has become the only innovative enterprise globally to have both liquid-helium-free MEG and MCG systems approved for market release.
Enze Kangtai
Entz Therapeutics is an innovative high-tech company dedicated to the development and clinical translation of exosome technology. By combining more than a decade of fundamental exosome research with molecular biology, cellular biology, and bioinformatics, it has established three proprietary exosome research and application platforms. The company has now built a GMP-compliant exosome production workshop exceeding 3,000 square meters and has established collaborations with thousands of hospitals, research institutions, and biotechnology companies both in China and internationally.
